The 5th iPSC Drug Development Summit serves as a pivotal platform for uniting iPSC-based drug developers across the value ...

XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received ...

Explore the functional analysis of compound responses in iPSC-derived 3D cardiac microtissues for insights into cardiac ...

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative ...

The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf ...

BACKGROUND: Dilated cardiomyopathy (DCM) is substantially influenced by genetic factors. Sarcomere function is intricately associated with other organelles, particularly the reciprocal regulation ...

Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China's ...

Laminin 521 (Cat. No. GMP-LA5H24) successfully maintained rapid expansion of human iPSCs, enabling cell passaging after just ...

Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower ...

The approval of XellSmart's clinical trial, along with the special exemption granted, signifies the FDA's recognition of XellSmart's well-established clinical-grade iPSC-derived cell drug development, ...

The partnership aims to industrialize the world’s first clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy for peripheral artery disease (PAD) and coronary artery ...